Viva Biotech Holdings Valuation
Is 1873 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 1873 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 1873's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 1873's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1873?
Key metric: As 1873 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 1873's PS Ratio? | |
|---|---|
| PS Ratio | 0.9x |
| Sales | CN¥2.00b |
| Market Cap | CN¥1.80b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.2x |
| Enterprise Value/EBITDA | 6.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 1873's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4x | ||
1521 Frontage Holdings | 1x | 15.9% | HK$2.0b |
2576 Zhejiang Taimei Medical Technology | 4.7x | 13.6% | HK$2.9b |
6118 Austar Lifesciences | 0.2x | n/a | HK$338.3m |
2268 WuXi XDC Cayman | 9.9x | 25.9% | HK$29.7b |
1873 Viva Biotech Holdings | 0.9x | n/a | HK$1.9b |
Price-To-Sales vs Peers: 1873 is good value based on its Price-To-Sales Ratio (0.9x) compared to the peer average (4x).
Price to Sales Ratio vs Industry
How does 1873's PS Ratio compare vs other companies in the Asian Life Sciences Industry?
| 6 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 6 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: 1873 is good value based on its Price-To-Sales Ratio (0.9x) compared to the Asian Life Sciences industry average (4.2x).
Price to Sales Ratio vs Fair Ratio
What is 1873's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.9x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 1873's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
China Shineway Pharmaceutical Group
HK$6.3b
An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.
2877
HK$8.29
7D
-5.1%
1Y
n/a
China Shineway Pharmaceutical Group
HK$6.3b
An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.
2877
HK$8.29
7D
-5.1%
1Y
n/a
Consun Pharmaceutical Group
HK$6.9b
Researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China.
1681
HK$8.37
7D
-3.3%
1Y
72.6%